StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Akari Therapeutics's enterprise value was $5.35M on Nov 11, 2026, against $13.38M a year earlier. Over the last 5 years it ranged from -$593.64K to $62.47M, with a median of $13.38M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$5.35M-23.0%
2025Dec 31, 2025$6.94M-45.6%
2024Dec 31, 2024$12.77M+48.3%
2023Dec 29, 2023$8.61M-56.4%
2022Dec 30, 2022$19.74M-63.4%
2021Dec 31, 2021$53.92M+38.7%
2020Dec 31, 2020$38.86M+87.9%
2019Dec 31, 2019$20.69M+147.4%
2018Dec 31, 2018$8.36M-59.9%
2017Dec 29, 2017$20.88M-23.0%
2016Dec 30, 2016$27.13M-70.5%
2015Dec 31, 2015$91.99M-63.3%
2014Dec 31, 2014$250.47M–

More Akari Therapeutics figures

See a number that looks wrong?